Research programme: gastrointestinal disease therapeutics - Altos Therapeutics

Drug Profile

Research programme: gastrointestinal disease therapeutics - Altos Therapeutics

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Altos Therapeutics
  • Class
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 01 Jul 2016 Altos Therapeutics enters into a definitive agreement with Takeda that includes an exclusive option for Takeda to acquire Altos
  • 09 Jan 2015 Altos Therapeutics receives patent allowance for its D2/D3 drug candidates in Mexico
  • 12 Feb 2014 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top